CVKD
NASDAQ
US
Cadrenal Therapeutics, Inc. - Common Stock
$4.70
▼ $-0.20
(-4.08%)
Vol 14K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$15.9M
ROE
-279.5%
D/E
0.00
Beta
1.04
52W
$7–$23
Wall Street Consensus
7 analysts · Apr 20262
Strong Buy
4
Buy
1
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating
Price Chart
Similar Stocks
HIND
Vyome Holdings Inc
$19.4M
CURX
Curanex Pharmaceuticals Inc
$9.4M
TRAW
Traws Pharma Inc
$9.0M
JUNS
Jupiter Neurosciences Inc
$35.1M
BFRI
Biofrontera Inc
$6.6M
CALC
CalciMedica Inc
$95.0M
RVPH
Reviva Pharmaceuticals Holdings Inc
$32.1M
HOTH
Hoth Therapeutics Inc
$15.4M
SNES
Senestech Inc
$11.1M
KPRX
Kiora Pharmaceuticals Inc
$7.2M
Earnings
Beat rate: 20.0%
Next Report
May 06, 2026
EPS Estimate: $-1.36
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-1.36 | — | — |
| Dec 2025 | $-1.19 | $-1.43 | $-0.24 |
| Sep 2025 | $-1.56 | $-1.31 | +$0.25 |
| Jun 2025 | $-1.63 | $-1.87 | $-0.24 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$2.4M | -$4.2M | -$3.8M | -$3.7M | -$2.7M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -265.4% | -265.4% | -265.4% | -265.4% | -279.5% | -279.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 3.56 | 3.56 | 3.56 | 3.56 | 3.02 | 3.02 |
Key Ratios
ROA (TTM)
-204.5%
P/B
3.5
EPS (TTM)
$-7.82
52W High
$22.90
52W Low
$6.75
$6.75
52-Week Range
$22.90
Financial Health
Free Cash Flow
-$2.4M
Cash
$3.9M
As of Sep 30, 2025
How does CVKD compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
CVKD valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(5.0)
vs Peers
vs Industry
Overvalued
P/B ratio
3.5
▲
64%
above
peers
(2.1)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
CVKD profitability vs Pharmaceuticals peers
ROE
-279.5%
▼
415%
below
peers
(-54.3%)
vs Peers
vs Industry
Weak
Net margin
—
▼
0%
below
peers
(-47.4%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(68.3%)
vs Peers
vs Industry
In line
ROA
-204.5%
▼
446%
below
peers
(-37.4%)
vs Peers
vs Industry
Weak
CVKD financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(1.5)
vs Peers
vs Industry
Low debt
Current ratio
3.0
▼
10%
below
peers
(3.4)
vs Peers
vs Industry
In line
Beta
1.0
▲
11%
above
peers
(0.9)
vs Peers
vs Industry
Less volatile
CVKD fundamentals radar
CVKD
Peer median
Industry
CVKD profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CVKD vs peers: key metrics
Latest News
No related news yet